Burning Rock Received Breakthrough Device Designation from China’s NMPA for its Multi-Cancer Early Detection Test
October 15, 2023 19:18 ET
|
Burning Rock Biotech Limited
Burning Rock Received Breakthrough Device Designation from China’s NMPA for its Multi-Cancer Early Detection Test
Shineco Subsidiary Receives Marketing Approval from China’s Regulatory Body for its Cardiac 5-Minute Test
July 10, 2023 09:00 ET
|
Shineco, Inc.
Registration with the NMPA, China’s Regulatory Equivalent to the FDA, is a Prerequisite to Marketing and Distribution BEIJING, July 10, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the...
Shineco Subsidiary’s ‘Cardiac 5-Minute Test’ Passes Quality Inspection by China Regulator NMPA
April 04, 2023 09:00 ET
|
Shineco, Inc.
Approval Provides Strong Support for the Product’s Marketing in China BEIJING, April 04, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer and...
Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter
July 20, 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
China National Medical Product Administration (NMPA) has granted Mabpharm approval to market INFLIXIMAB biobetter in China.Sorrento holds commercialization rights outside of China and intends to meet...
Priority Review Granted to BeiGene’s Supplemental New Drug Application in China for Tislelizumab in Urothelial Carcinoma
July 07, 2019 20:00 ET
|
BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., July 07, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for Tislelizumab in Urothelial Carcinoma
May 30, 2019 19:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, May 30, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...